Interleukin and interleukin receptor diversity: Role of alternative splicing

International Reviews of Immunology

Volumn 29, Issue 1, 2010, Pages 77-109

  Sahoo, Anupama ^a   Im, Sin Hyeog ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Alternative splicing; Immune system; Interleukin; Interleukin receptor

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 18 RECEPTOR BETA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 20 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 32; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; INTERLEUKIN 9 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA PRECURSOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ALTERNATIVE SPLICING; ANIMALS; DOGS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; IMMUNE SYSTEM; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; RATS; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

EID: 76149108442     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830180903349651     Document Type: Review

References (195)

1. LA Miosge and CC Goodnow. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol Cell Biol 2005;83:318-335.
2. Y-F Chang, JS Imam, and MF Wilkinson. The nonsense-mediated decay RNA surveillance pathway. Ann Rev Biochem 2007;76:51-74.
3. B Modrek and CJ Lee. Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet 2003;34:177-180.
4. S Gerondakis, R Grumont, I Rourke, and M Grossmann. The regulation and roles of Rel/NF-[kappa]B transcription factors during lymphocyte activation. Curr Opin Immunol 1998;10:353-359.
5. T Moroy. The zinc finger transcription factor growth factor independence 1 (Gfi1). Intl J Biochem Cell Biol 2005;37:541.
6. KW Lynch. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 2004;4:931-940.
7. SP Atamas. Alternative splice variants of cytokines: Making a list. Life Sci 1997;61:1105-1112.
8. ML Heaney and DW Golde. Soluble cytokine receptors. Blood 1996;87:847-857.
9. OP Yatsenko, ML Filipenko, EA Khrapov, et al. Alternative splicing of mRNA of mouse interleukin-4 and interleukin-6. Cytokine 2004;28:190-196.
10. G Ast. How did alternative splicing evolve? Nat Rev Genet 2004;5:773-782.
11. E Kim, A Goren, and G Ast. Alternative splicing: Current perspectives. Perspective 2008;30:38-47.
12. CWSugnet,WJ Kent,MAres, Jr, and DHaussler. Transcriptome and genome conservation of alternative splicing events in humans and mice. Pac Symp Biocomput 66-77, 2004.
13. DL Black. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;72:291-336.
14. CWJ Smith and J Valcarcel. Alternative pre-mRNA splicing: The logic of combinatorial control. Trends Biochem Sci 2000;25:381-388.
15. A Astier, H De la Salle, C De la Salle, et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells. J Immunol 1994;152:201-212.
16. TP Atkinson, CG Hall, J Goldsmith, and PM Kirkham. Splice variant in TCR links T cell receptor signaling to a G-protein-related signaling pathway. Biochem & Biophys Res Commun 2003;310:761-766.
17. A Ishitani and DE Geraghty. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci 1992;89:3947-3951.
18. G Yan, L Shi, and D Faustman. Novel splicing of the human MHC-encoded peptide transporter confers unique properties 1. J Immunol 1999;162:852-859.
19. JY Ip, A Tong, Q Pan, et al. Global analysis of alternative splicing during T-cell activation. RNA 2007;13:563-572.
20. JR Leeman and TD Gilmore. Alternative splicing in the NF-[kappa]B signaling pathway. Gene 2008;423:97-107.
21. D Davidson, LM Chow, M Fournel, and A Veillette. Differential regulation of T cell antigen responsiveness by isoforms of the SRC-related tyrosine protein kinase p59fyn. J Exp Med 1992;175:1483-1492.
22. S Latour, J Zhang, RP Siraganian, and A Veillette. A unique insert in the linker domain of Syk is necessary for its function in immunoreceptor signalling. EMBO J 1998;17:2584-2595.
23. PD King, ET Sandberg, A Selvakumar, et al. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J Immunol 1995;154:6080-6093.
24. Y Wang and N Sheibani. Expression pattern of alternatively spliced PECAM-1 isoforms in hematopoietic cells and platelets. J Cell Biochem 2002;87:424-438.
25. SB Fox, J Fawcett, DG Jackson, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-4546.
26. H Ponta, L Sherman, and PA Herrlich. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
27. AE House and KW Lynch. An exonic splicing silencer represses spliceosome assembly after ATP-dependent exon recognition. Nat Struct Mol Biol 2006;13:937-944.
28. A Tong, J Nguyen, and KW Lynch. Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicingregulatory elements in each of the variable exons. J Biol Chem 2005;280:38297-38304.
29. CA Dinarello. Biologic basis for interleukin-1 in disease. Blood 1996;87: 2095-2147.
30. JG Giri, PT Lomedico, and SB Mizel. Studies on the synthesis and secretion of interleukin 1. I. A 33,000 molecular weight precursor for interleukin 1. J Immunol 1985;134:343-349.
31. T Sultana, K Svechnikov, GWeber, and O Soder.Molecular cloning and expression of a functionally different alternative splice variant of prointerleukin-1{{alpha}} from the rat testis. Endocrinology 2000;141:4413-4418.
32. AF Straubinger, MM Viveiros, and RK Straubinger. Identification of two transcripts of canine, feline, and porcine interleukin-1 alpha. Gene 1999;236:273-280.
33. L Kiczak, U Paslawska, J Bania, et al. Increased expression of interleukin-1[beta] and its novel splice variant in canine hearts with volume overload. Cytokine 2008;44:352-360.
34. JZ Jun, C Charles, and JS Christopher. The rainbow trout Oncorhynchus mykiss interleukin-1?; gene has a different organization to mammals and undergoes incomplete splicing. Euro J Biochem 1999;259:901-908.
35. H Kato, H-Y Youn, T Ohashi, et al. Identification of an alternatively spliced transcript of equine interleukin-1[beta]. Gene 1996;177:11-16.
36. M Ferretti, V Casini-Raggi, TT Pizarro, et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Investiga 1994;94:449-453.
37. M Malyak, RE Swaney, and WP Arend. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthr & Rheum 1993;36:781-789.
38. MMalyak, MF Smith, Jr, AA Abel, et al. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol 1998;161:2004-2010.
39. C Butcher, A Steinkasserer, S Tejura, and AC Lennard. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 1994;153:701-711.
40. CF Bigler, DA Norris, WL Weston, and WP Arend. Interleukin-1 receptor antagonist production by human keratinocytes. J Investig Dermatol 1992;98: 38-44.
41. S Haskill, G Martin, L Van Le, et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci 1991;88:3681-3685.
42. LAJ O'Neill. Towards an understanding of the signal transduction pathways for interleukin 1. BBA-Molec Cell Res 1995;1266:31-44.
43. M Yamada, M Nishizawa, R Nakatake, et al. Characterization of alternatively spliced isoforms of the type I interleukin-1 receptor on iNOS induction in rat hepatocytes. Nitric Oxide 2007;17:98-105.
44. C Liu, RP Hart, X-J Liu, et al. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 1996;271:20965-20972.
45. A Vambutas, J DeVoti, E Goldofsky, et al. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS ONE 2009;4:e5293.
46. S Gillis, MM Ferm, W Ou, and KA Smith. T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 1978;120:2027-2032.
47. DA Morgan, FW Ruscetti, and R Gallo. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-1008.
48. MC Howard, A Miyajima, and R Coffman. T-cell-derived cytokines and their receptors. Fundamen Immunol. Raven Press; 1993. pp. 763-833.
49. VN Tsytsikov, VV Yurovsky, SP Atamas, et al. Identification and characterization of two alternative splice variants of human interleukin-2. J Biol Chem 1996;271:23055-23060.
50. AL Janezic, M Bukilica, GV Jones, et al. Alternatively spliced variants of IL-2 mRNA in sequential transplant kidney core needle biopsies. Transplan Proc 2001;33:383-386.
51. T Taniguchi and Y Minami. The IL-2/IL-2 receptor system: A current overview. Cell 1993;73:5-8.
52. LA Rubin,CCKurman,MEFritz, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172-3177.
53. D Novick, H Engelmann, DWallach, andMRubinstein. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989;170:1409-1414.
54. WJ Leonard, JM Depper, M Kanehisa, et al. Structure of the human interleukin-2 receptor gene. Science 1985;230:633-639.
55. LMarcon, ME Fritz, CC Kurman, et al. Soluble Tac peptide is present in the urine of normal individuals and at elevated levels in patients with adult T cell leukaemia (ATL). Clin Exper Immunol 1988;73:29-33.
56. S Horiuchi, Y Koyanagi, Y Tanaka, et al. Altered interleukin-2 receptor alphachain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Immunology 1997;91:28-34.
57. T Yokota, T Otsuka, T Mosmann, et al. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell-and T-cell-stimulating activities. Proc Natl Acad Sci 1986;83:5894-5898. (Pubitemid 16000620)
58. RV Sorg, J Enczmann, UR Sorg, et al. Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Experi Hematol 1993;21:560-563.
59. Y Arinobu, SP Atamas, T Otsuka, et al. Antagonistic effects of an alternative splice variant of human IL-4, IL-4d2, on IL-4 activities in human monocytes and B cells. Cell Immunol 1999;191:161-167.
60. SP Atamas, VV Yurosovy, R Wise, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthr & Rheum 1999;42:1168-1178.
61. WJ Alms, SP Atamas, VV Yurovsky, and B White. Generation of a variant of human interleukin-4 by alternative splicing. Mol Immunol 1996;33:361-370.
62. HD Perkins, BH van Leeuwen, CM Hardy, and PJ Kerr. The complete cDNA sequences of IL-2, IL-4, IL-6 and IL-10 from the European rabbit (Oryctolagus cuniculus). Cytokine 2000;12:555-565.
63. LI Sakkas, C Tourtellotte, S Berney, et al. Increased levels of alternatively spliced interleukin 4 (IL-4d2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin & Diag Lab Immunol 1999;6:660-664.
64. GT Seah, PS Gao, JM Hopkin, and GAW Rook. Interleukin-4 and its alternatively spliced variant (IL-4delta 2) in patients with atopic asthma. Am J Respir Crit Care Med 2001;164:1016-1018.
65. AF Helen, O Patrick, J David, et al. Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4d2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology 2004;112:669-673.
66. K Dheda, JS Chang, JF Huggett, et al. The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4 2, is not. Tuberculosis 2007;87:237-241.
67. Z Yuan, R Wang, Y Lee, et al. Tuberculosis-induced variant IL-4 mRNA encodes a cytokine functioning as growth factor for (E)-4-hydroxy-3-methyl-but- 2-enyl pyrophosphate-specific V{gamma}2V{delta}2 T cells. J Immunol 2009;182:811-819.
68. SM Russell, AD Keegan, N Harada, et al. Interleukin-2 receptor gamma chain: A functional component of the interleukin-4 receptor. Science 1993;262:1880-1883.
69. H Blum, M Wolf, K Enssle, et al. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol 1996;157: 1846-1853.
70. S Kruse, J Forster, J Kuehr, and KA Deichmann. Characterization of the membrane-bound and a soluble form of human IL-4 receptor a produced by alternative splicing. Intl Immunol 1999;11:1965-1970.
71. B Ann-Marie, B Barbro, K Shivendra, et al. Common variations in the IL4R gene affect splicing and influence natural expression of the soluble isoform. Human Mutat 2006;27:990-998.
72. CJ Bagley, JM Woodcock, FC Stomski, and AF Lopez. The structural and functional basis of cytokine receptor activation: Lessons from the common ? subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood, 89:1471-1482, 1997.
73. J Tavernier, R Devos, S Cornelis, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991;66:1175-1184.
74. J Tavernier, T Tuypens, G Plaetinck, et al. Molecular basis of the membraneanchored and two soluble isoforms of the human interleukin 5 receptor subunit. Proc Natl Acad Sci 1992;89:7041-7045.
75. S Takaki, A Tominaga, Y Hitoshi, et al. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 1990;9:4367-4374.
76. IF Imamura, S Takaki, K Akagi, et al. The murine interleukin-5 receptor-subunit gene: characterization of the gene structure and chromosome mapping. DNA Cell Biol 1994;13:283-292.
77. Y Kikuchi, M Migita, S Takaki, et al. Biochemical and functional characterization of soluble form of IL-5 receptor a (sIL-5Ra): Development of ELISA system for detection of sIL-5Ra. J Immunol Methods 1994;167:289-298.
78. K Takatsu, S Takaki, and Y Hitoshi. Interleukin-5 and its receptor system: Implications in the immune system and inflammation. Adv Immunol 1994;57:145-190.
79. J Tavernier, J Van Der Heyden, A Verhee, et al. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. Blood 2000;95:1600-1607.
80. JG Karras, RA McKay, NM Dean, and BP Monia. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol Pharmacol 2000;58:380-387.
81. C Lins and R Borojevic. Interleukin-5 receptor alpha chain expression and splicing during brain development in mice. Growth Factors 2001;19:145-152.
82. M Rincon, J Anguita, T Nakamura, et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997;185:461-470.
83. GYXu,HA Yu, JHong, et al. Solution structure of recombinant human interleukin-6. J Mol Biol 1997;268:468-481.
84. MP Bihl, K Heinimann, JJ Rudiger, et al. Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor. Am J Respir Cell & Mol Biol 2002;27:48-56.
85. DP Kestler, S Agarwal, J Cobb, et al. Detection and analysis of an alternatively spliced isoform of interleukin-6 mRNA in peripheral blood mononuclear cells. Blood 1995;86:4559-4567.
86. L Alberti, T Bachelot, A Duc, et al. A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res 2005;65:2-5.
87. PC Heinrich, I Behrmann, and L Graeve. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J London 1998;334:297-314.
88. G Muller-Newen, A Kuster, U Hemmann, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998;161:6347-6355.
89. S Yang, S Hu, MA Choudhry, et al. Anti-rat soluble IL-6 receptor antibody down-regulates cardiac IL-6 and improves cardiac function following traumahemorrhage. J Mol & Cell Cardiol 2007;42:620-630.
90. F De Benedetti, M Massa, P Pignatti, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Investig 1994;93:2114-2119.
91. MHonda, S Yamamoto,MCheng, et al. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-2180.
92. JA Hoyland, AJ Freemont, and PT Sharpe. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Min Res 1994;9: 75-80.
93. S Horiuchi, W Ampofo, Y Koyanagi, et al. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy. Immunology 1998;95:360-369.
94. TJ Fry and CL Mackall. The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance. J Immunol 2005;174:6571-6576.
95. KS Schluns, WC Kieper, SC Jameson, and L Lefrancois. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-432.
96. O Alpdogan, SJ Muriglan, JM Eng, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Investig 2003;112:1095-1107.
97. SAYHartgring, JWJ Bijlsma, F Lafeber, and JAG van Roon. Interleukin-7 induced immunopathology in arthritis. Annals Rheum Dis 2006;65:iii69-iii74.
98. BE Rich, J Campos-Torres, RI Tepper, et al. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exper Medi 1993;177:305-316.
99. I Roato, EVA Gorassini, G Brunetti, et al. IL-7 modulates osteoclastogenesis in patients affected by solid tumors. Ann New York Acad Sci 2007;1117:377-384.
100. J Frishman, B Long, W Knospe, et al. Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. J Exper Medi 1993;177:955-964.
101. A Korte, A Moricke, B Beyermann, et al. Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells: Implication of distinct isoforms in modulating IL-7 activity. J Interfer & Cytok Res 1999;19:495-503.
102. NK Vudattu, I Magalhaes, H Hoehn, et al. Expression analysis and functional activity of interleukin-7 splice variants. Genes & Immun 2008;10:132-140.
103. RG Goodwin, D Friend, SF Ziegler, et al. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990;60:941-951.
104. CM Pleiman, SD Gimpel, LS Park, et al. Organization of the murine and human interleukin-7 receptor genes: Two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter. Mol Cell Biol 1991;11:3052-3059.
105. A Korte, J Kochling, L Badiali, et al. Expression analysis and characterization of alternatively spliced transcripts of human IL-7R chain encoding two truncated receptor proteins in relapsed childhood ALL. Cytokine 2000;12:1597-1608.
106. YC Yang, S Ricciardi, A Ciarletta, et al. Expression cloning of cDNA encoding a novel human hematopoietic growth factor: Human homologue of murine T-cell growth factor P40. Blood 1989;74:1880-1884.
107. JB Demoulin and JC Renauld. Interleukin 9 and its receptor: An overview of structure and function. Intl Rev Immunol 1998;16:345-364.
108. L Grasso, M Huang, CD Sullivan, et al. Molecular analysis of human interleukin-9 receptor transcripts in peripheral blood mononuclear cells. Identification of a splice variant encoding for a nonfunctional cell surface receptor. J Biol Chem 1998;273:24016-24024. (Pubitemid 28435742)
109. KW Moore, R de Waal Malefyt, RL Coffman, and A O'Garra. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001;19:683-765.
110. S Pestka, CD Krause, D Sarkar, et al. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 2004;22:929-979.
111. VP Khatri and MA Caligiuri. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998;46:239-244.
112. S Wu, R Gessner, T Taube, et al. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:3038-3042.
113. AM Cooper, J Magram, J Ferrante, and IM Orme. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exper Medi 1997;186:39-45.
114. G Trinchieri. Interleukin-12 and its role in the generation of TH1 cells. Trends Immunol 1993;14:335-338.
115. MP Hayes, FJ Murphy, and PR Burd. Interferon-gamma-dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the CpG-rich promoter active in Epstein-Barr virus-transformed lymphoblastoid cells. Blood 1998;91:4645-4651.
116. XMa, and LJMontaner. Proinflammatory response and IL-12 expression in HIV-1 infection. Journal of Leukocyte Biology 2000;68:383-390.
117. MP Hayes, J Wang, and MA Norcross. Regulation of interleukin-12 expression in human monocytes: Selective priming by interferon-gamma of lipopolysaccharideinducible p35 and p40 genes. Blood 1995;86:646-650.
118. A Snijders, CM Hilkens, TC Van Der Pouw Kraan, et al. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol 1996;156:1207-1212.
119. JM Babik, E Adams, Y Tone, et al. Expression of murine IL-12 is regulated by translational control of the p35 subunit. J Immunol 1999;162:4069-4078.
120. U Johansson, SP Cooke, and M Londei. Identification of a new isoform of human IL-12 p35 mRNA. Euro J Immunogenetics 2002;29:439-444.
121. DH Presky, H Yang, LJ Minetti, et al. A functional interleukin 12 receptor complex is composed of two-type cytokine receptor subunits. Proc Natl Acad Sci 1996;93:14002-14007.
122. F Okano, M Satoh, and K Yamada. Cloning and expression of the cDNA for canine interleukin-12. J Interfer & Cytok Res 1997;17:713-718.
123. BS Phillips, ML Padilla, EB Dickerson, et al. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Veteri Immunol & Immunopathol 1999;70:189-201.
124. E Kitamiya, T Iwasaki, and Y Momoi. Molecular cloning of interleukin-12 receptor 2 chain and its expression in dogs. Veteri Immunol & Immunopathol 2005;106:221-228.
125. A Minty, P Chalon, JM Derocq, et al. lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248-250.
126. M Wills-Karp, J Luyimbazi, X Xu, et al. Interleukin-13: Central mediator of allergic asthma. Science 1998;282:2258-2261.
127. M Akaiwa, B Yu, R Umeshita-Suyama, et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 2001;13:75-84.
128. JF Gauchat, E Schlagenhauf, NP Feng, et al. A novel 4-kb interleukin-13 receptor mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Euro J Immunol 1997;27:971-978.
129. P Graber, D Gretener, S Herren, et al. The distribution of IL-13 receptor 1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4. Euro J Immunol 1998;28:4286-4298.
130. DD Donaldson, MJ Whitters, LJ Fitz, et al. The murine IL-13 receptor 2: Molecular cloning, characterization, and comparison with murine IL-13 receptor 1 1. J Immunol 1998;161:2317-2324.
131. M Khodoun, C Lewis, J-Q Yang, et al. Differences in expression, affinity, and function of soluble (s)IL-4R{alpha} and sIL-13R{alpha}2 suggest opposite effects on allergic responses. J Immunol 2007;179:6429-6438.
132. Y Tabata, W Chen, MR Warrier, et al. Allergy-driven alternative splicing of IL-13 receptor {alpha}2 yields distinct membrane and soluble forms. J Immunol 2006;177:7905-7912.
133. KH Grabstein, J Eisenman, K Shanebeck, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-968. (Pubitemid 24196167)
134. H Nishimura, J Washizu, N Nakamura, et al. Translational efficiency is upregulated by alternative exon in murine IL-15 mRNA. J Immunol 1998;160: 936-942.
135. H Nishimura, T Yajima, Y Naiki, et al. Differential roles of interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo. J Exp Med 2000;191:157-170.
136. H Nishimura, A Fujimoto, N Tamura, et al. A novel autoregulatory mechanism for transcriptional activation of the IL-15 gene by a nonsecretable isoform of IL-15 generated by alternative splicing. FASEB J 2005;19:19-28.
137. X Tan and L Lefrancois. Novel IL-15 isoforms generated by alternative splicing are expressed in the intestinal epithelium. Genes & Immun 2006;7:407-416.
138. G Genova, IU Inserm, and H Paul. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: Role of different signal peptides. Eur J Immunol 1997;27:1049-1054.
139. DM Anderson, S Kumaki, M Ahdieh, et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995;270:29862-29869.
140. S Dubois, F Magrangeas, P Lehours, et al. Natural splicing of Exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression. J Biol Chem 1999;274:26978-26984.
141. JG Giri, S Kumaki, M Ahdieh, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the chain of the IL-2 receptor. EMBO J 1995;14:3654-3654
142. E Bulanova, V Budagian, Z Orinska, et al. Mast cells express novel functional IL-15 receptor isoforms 1. J Immunol 2003;170:5045-5055.
143. E Bulanova,V Budagian, E Duitman, et al. Soluble interleukin (IL)-15R? is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 2007;282:13167-13179.
144. TA Moseley, DR Haudenschild, L Rose, and AH Reddi. Interleukin-17 family and IL-17 receptors. Cytokine & Growth Factor Rev 2003;14:155-174.
145. E Lubberts. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003;4:572-577.
146. FMcAllister, AHenry, JL Kreindler, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis 1. J Immunol 2005;175:404-412.
147. N Oda, PB Canelos, DM Essayan, et al. Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response. Am J Respir Crit Care Med 2005;171:12-18.
148. RE Kuestner, DW Taft, A Haran, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007;179:5462-5473.
149. MTsang,RFriesel, TKudoh, and IB Dawid. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 2002;4:165-169.
150. D Haudenschild, T Moseley, L Rose, and AH Reddi. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002;277:4309-4316.
151. DR Haudenschild, SB Curtiss, TA Moseley, and AH Reddi. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. The Prostate 2006;66:1268-1274.
152. AJ Puren, G Fantuzzi, and CA Dinarello. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1? are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci 1999;96:2256-2261.
153. K Takeda, H Tsutsui, T Yoshimoto, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-390.
154. S Ushio, M Namba, T Okura, et al. Cloning of the cDNA for human IFN-gammainducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. Journal Immunol 1996;156:4274-4279.
155. T Hoshino, RH Wiltrout, and HA Young. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response 1 2. J Immunol 1999;162:5070-5077.
156. MG Netea, BJ Kullberg, I Verschueren, and J Meer. Interleukin-18 induces production of proinflammatory cytokines in mice: No intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1. Euro J Immunol 2000;30:3057-3060.
157. T Ghayur, S Banerjee, M Hugunin, et al. Caspase-1 processes IFN-gammainducing factor and regulates LPS-induced IFN-gamma production. Nature 1997;386:619-623.
158. A Gaggero, A De Ambrosis, D Mezzanzanica, et al. A novel isoform of prointerleukin-18 expressed in ovarian tumors is resistant to caspase-1 and-4 processing. Oncogene 2004;23:7552-7560.
159. J Zou, S Bird, J Truckle, et al. Identification and expression analysis of an IL-18 homologue and its alternatively spliced form in rainbow trout (Oncorhynchus mykiss). Euro J Biochem 2004;271:1913-1923.
160. B Conti, JW Jahng, C Tinti, et al. Induction of interferon-gamma inducing factor in the adrenal cortex. J Biol Chem 1997;272:2035-2037.
161. Y-J Yang, Z-Y Wang, S-H Chen, and X-R Ge. Cloning and characterization of a new isoform of mouse interleukin-18. Acta Biochim Biophys Sin 2005;37:826-834.
162. TL Born, LA Morrison, DJ Esteban, et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 2000;164:3246-3254.
163. S-H Kim,MEisenstein, L Reznikov, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci 2000;97:1190-1195.
164. RDWheeler and PDCollins. Identification of a truncated IL-18R beta mRNA: A putative regulator of IL-18 expressed in rat brain. J Neuroimmunoi 2003;145:40-45.
165. D Fiszer, N Rozwadowska, L Rychlewski, et al. Identification of IL-18RAP mRNA truncated splice variants in human testis and the other human tissues. Cytokine 2007;39:178-183.
166. S Commins, JW Steinke, and L Borish. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy & Clin Immunol 2008;121:1108-1111.
167. CC Wei and MS Chang. A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes & Immun 2008;9:668-679.
168. WJ Leonard and R Spolski. Interleukin-21: Amodulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005;5:688-698.
169. M Rahman, H Nara, T Onoda, et al. Cloning and characterization of an isoform of interleukin-21. FEBS Lett 2007;581:4001-4009.
170. KWolk, S Kunz, K Asadullah, and R Sabat. Cutting edge: Immune cells as sources and targets of the IL-10 family members?. J Immunol 2002;168:5397-5402.
171. K Wolk, S Kunz, E Witte, et al. IL-22 increases the innate immunity of tissues. Immunity 2004;21:241-254.
172. LA Zenewicz, GD Yancopoulos, DM Valenzuela, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007;27:647-659.
173. SJ Aujla, YR Chan, M Zheng, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Medicine 2008;14:275-281.
174. Y Zheng, PA Valdez, DM Danilenko, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Medicine 2008;14:282-289.
175. L Dumoutier, D Lejeune, D Colau, and JC Renauld. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001;166:7090-7095.
176. SV Kotenko, LS Izotova, OV Mirochnitchenko, et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity 1 2. J Immunol 2001;166:7096-7103.
177. W Xu, SR Presnell, J Parrish-Novak, et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci 2001;98:9511-9516.
178. BH Gruenberg, A Schoenemeyer, B Weiss, et al. A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta. Genes & Immun 2001;2:329-334.
179. C Parham, M Chirica, J Timans, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R 1 and a novel cytokine receptor subunit, IL-23R 1. J Immunol 2002;168:5699-5708.
180. Z Waibler, U Kalinke, J Will, et al. TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells. Mol Immunol 2007;44:1483-1489.
181. CT Weaver, RD Hatton, PR Mangan, and LE Harrington. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Ann Rev Immunol 2007;25:821-852.
182. XY Zhang, HJ Zhang, Y Zhang, et al. Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells. Immunogenetics
183. S Kan, G Mancini, and G Gallagher. Identification and characterization of multiple splice forms of the human interleukin-23 receptor chain in mitogen-activated leukocytes. Genes & Immunity 2008;9:631-639.
184. H Jiang, ZZ Su, JJ Lin, et al. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci 1996;93:9160-9165.
185. IV Lebedeva,MSauane, RVGopalkrishnan, et al. mda-7/IL-24: Exploiting cancer's achilles' heel. Mol Ther 2005;11:4-18.
186. M Allen, B Pratscher, F Roka, et al. Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma 1. J. Investig Dermatol 2004;123:583-588.
187. A Sahoo, YM Jung, H-K Kwon, et al. A novel splicing variant of mouse interleukin (IL)-24 antagonizes IL-24-induced apoptosis. J Biol Chem 2008;283:28860-28872.
188. S Kim, S Han, T Azam, et al. Interleukin-32 A cytokine and inducer of TNF. Immunity 2005;22:131-142.
189. LAB Joosten, MG Netea, SH Kim, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci 2006;103:3298-3303.
190. M Shioya, A Nishida, Y Yagi, et al. Epithelial overexpression of interleukin-32 in inflammatory bowel disease. Clin Exper Immunol 2007;149:480-486.
191. C Goda, T Kanaji, S Kanaji, et al. Involvement of IL-32 in activation-induced cell death in T cells. Intl Immunol 2006;18:233-240.
192. N-Y Ko, S-H Chang, J-H Lee, et al. Unique expression of a small IL-32 protein in the Jurkat leukemic T cell line. Cytokine 2008;42:121-127.
193. I Dikic and J Schlessinger. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem 1998;273:14301-14308.
194. LE Jensen and AS Whitehead. IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J Biol Chem 2001;276:29037-29044.
195. K Burns, S Janssens, B Brissoni, et al. Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003;197:263-268.